Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Ascending) Package Effective Date Package Discontinuation Date Status
67457-0864-04 67457-0864 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous March 21, 2018 In Use
50881-0006-03 50881-0006 Retifanlimab-dlwr ZYNYZ 25.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous March 22, 2023 In Use
00781-3201-94 00781-3201 Levoleucovorin Levoleucovorin 175.0 mg/17.5mL Ancillary Therapy Chemoprotective Antidote Intravenous April 23, 2015 April 30, 2023 No Longer Used
16714-0928-01 16714-0928 Decitabine Decitabine 50.0 mg/10mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 18, 2019 In Use
16729-0246-05 16729-0246 Mitomycin Mitomycin 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 3, 2013 April 30, 2023 No Longer Used
16729-0247-11 16729-0247 Mitomycin Mitomycin 20.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 3, 2013 Feb. 28, 2023 No Longer Used
16729-0248-38 16729-0248 Mitomycin Mitomycin 40.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 3, 2013 Jan. 31, 2023 No Longer Used
25021-0451-01 25021-0451 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 In Use
25021-0452-01 25021-0452 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 Jan. 31, 2023 In Use
25021-0453-01 25021-0453 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 Feb. 28, 2023 In Use
25021-0454-05 25021-0454 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 March 31, 2021 In Use
67457-0513-05 67457-0513 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Jan. 1, 2018 In Use
67457-0513-99 67457-0513 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Jan. 1, 2018 In Use
42658-0010-01 42658-0010 Cladribine Cladribine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous May 18, 2020 In Use
42658-0010-02 42658-0010 Cladribine Cladribine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous April 1, 2020 In Use
42658-0010-91 42658-0010 Cladribine Cladribine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Feb. 28, 2023 In Use
42658-0021-01 42658-0021 Daunorubicin hydrochloride Daunorubicin Hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jan. 20, 2020 In Use
42658-0021-02 42658-0021 Daunorubicin hydrochloride Daunorubicin Hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jan. 27, 2021 In Use
42658-0021-92 42658-0021 Daunorubicin hydrochloride Daunorubicin Hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 19, 2022 In Use
42658-0021-91 42658-0021 Daunorubicin hydrochloride Daunorubicin Hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jan. 15, 2023 In Use
00409-0004-04 00409-0004 PEMETREXED PEMETREXED 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Feb. 1, 2023 In Use
00409-0020-02 00409-0020 PEMETREXED PEMETREXED 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Feb. 1, 2023 In Use
00409-0021-03 00409-0021 PEMETREXED PEMETREXED 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Feb. 1, 2023 In Use
00527-1242-02 00527-1242 Fludarabine Phosphate Fludarabine Phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Dec. 31, 2019 In Use
25021-0226-10 25021-0226 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Feb. 15, 2023 In Use
25021-0227-06 25021-0227 Arsenic Trioxide Arsenic Trioxide 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Feb. 15, 2023 In Use
46708-0678-02 46708-0678 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 28, 2023 In Use
46708-0678-08 46708-0678 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 28, 2023 In Use
46708-0678-16 46708-0678 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 28, 2023 In Use
43598-0142-06 43598-0142 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 9, 2023 In Use
43598-0142-11 43598-0142 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous March 1, 2023 In Use
46708-0620-05 46708-0620 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
46708-0621-17 46708-0621 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
46708-0622-50 46708-0622 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
46708-0751-50 46708-0751 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous March 3, 2023 In Use
47426-0401-10 47426-0401 APREPITANT APONVIE 32.0 mg/4.4mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous March 6, 2023 In Use
51407-0748-02 51407-0748 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous March 20, 2023 In Use
51407-0749-05 51407-0749 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous March 20, 2023 In Use
51407-0750-10 51407-0750 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous March 20, 2023 In Use
62756-0581-40 62756-0581 Amifostine Amifostine 50.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous March 14, 2008 March 31, 2012 No Longer Used
62756-0581-42 62756-0581 Amifostine Amifostine 50.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous March 14, 2008 March 31, 2012 No Longer Used
62856-0798-01 62856-0798 Palonosetron hydrochloride Aloxi 0.075 mg/1.5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 28, 2014 June 30, 2018 In Use
63323-0735-10 63323-0735 Pamidronate Disodium Pamidronate Disodium 9.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous May 19, 2002 Aug. 27, 2015 In Use
66220-0017-03 66220-0017 Amifostine Ethyol 500.0 mg/10mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Aug. 1, 2016 Oct. 31, 2020 No Longer Used
67457-0472-10 67457-0472 Pamidronate Disodium Pamidronate Disodium 3.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous May 10, 2011 Nov. 30, 2018 No Longer Used
69097-0927-35 69097-0927 Palonosetron hydrochloride Palonosetron hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous March 23, 2018 In Use
11994-0016-01 11994-0016 samarium Sm 153 lexidronam Quadramet 50.0 mCi/mL Ancillary Therapy Radiopharmaceutical Samarium Sm 153 Intravenous May 19, 1997 In Use
16714-0727-01 16714-0727 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 15, 2017 In Use
16714-0728-01 16714-0728 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 15, 2017 In Use
23155-0356-32 23155-0356 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 29, 2021 June 30, 2021 In Use
23155-0356-41 23155-0356 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 29, 2021 June 30, 2021 In Use
68001-0370-27 68001-0370 Cyclophosphamide Cyclophosphamide 500.0 mg/25mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Nov. 23, 2018 March 31, 2022 No Longer Used
68001-0371-32 68001-0371 Cyclophosphamide Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Nov. 23, 2018 March 31, 2022 No Longer Used
68001-0372-32 68001-0372 Cyclophosphamide Cyclophosphamide 2.0 g/100mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Nov. 23, 2018 March 31, 2022 No Longer Used
68152-0109-00 68152-0109 Melphalan Evomela 50.0 mg/10mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous March 31, 2016 March 31, 2022 No Longer Used
57894-0111-01 57894-0111 ciltacabtagene autoleucel CARVYKTI 100000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Feb. 28, 2022 In Use
57894-0111-02 57894-0111 ciltacabtagene autoleucel CARVYKTI 100000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Feb. 28, 2022 In Use
69488-0010-61 69488-0010 Lutetium Lu 177 vipivotide tetraxetan PLUVICTO 27.0 mCi/mL Radiopharmaceutical Radiopharmaceutical PSMA Intravenous March 23, 2022 In Use
43598-0143-62 43598-0143 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous April 20, 2022 In Use
24979-0710-51 24979-0710 Paclitaxel Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous April 1, 2022 In Use
60505-6230-04 60505-6230 Paclitaxel Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous April 1, 2022 In Use
55150-0355-01 55150-0355 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous April 11, 2022 In Use
71288-0169-25 71288-0169 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Feb. 28, 2022 In Use
70121-1569-07 70121-1569 Filgrastim RELEUKO 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70121-1571-07 70121-1571 Filgrastim RELEUKO 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
68083-0535-10 68083-0535 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous April 22, 2022 In Use
68001-0524-30 68001-0524 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 18, 2022 In Use
68001-0524-31 68001-0524 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 18, 2022 In Use
68001-0525-27 68001-0525 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 18, 2022 In Use
68001-0525-32 68001-0525 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 18, 2022 In Use
44567-0505-01 44567-0505 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 11, 2013 April 30, 2022 No Longer Used
44567-0504-01 44567-0504 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 11, 2013 April 30, 2022 No Longer Used
44567-0506-01 44567-0506 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 11, 2013 April 30, 2022 No Longer Used
71288-0143-02 71288-0143 Docetaxel anhydrous Docetaxel anhydrous 20.0 mg/2mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 24, 2018 In Use
23155-0685-31 23155-0685 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 25, 2022 In Use
23155-0686-31 23155-0686 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 25, 2022 In Use
50242-0087-01 50242-0087 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb. 22, 2013 In Use
50242-0088-01 50242-0088 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb. 22, 2013 In Use
55150-0352-01 55150-0352 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 11, 2020 In Use
55150-0353-01 55150-0353 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 11, 2020 In Use
55150-0354-01 55150-0354 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 11, 2020 In Use
17478-0547-01 17478-0547 Granisetron Hydrochloride Granisetron Hydrochloride 0.1 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2009 In Use
51991-0065-97 51991-0065 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous May 1, 2020 May 2, 2020 No Longer Used
51991-0065-98 51991-0065 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Sept. 15, 2017 May 31, 2022 No Longer Used
68001-0366-25 68001-0366 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Oct. 5, 2018 May 31, 2022 No Longer Used
68001-0366-87 68001-0366 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Feb. 10, 2020 Aug. 24, 2021 No Longer Used
55513-0126-01 55513-0126 Epoetin alfa Epogen 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 30, 1989 In Use
55513-0126-10 55513-0126 Epoetin alfa Epogen 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 30, 1989 In Use
55513-0144-01 55513-0144 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0144-10 55513-0144 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0148-01 55513-0148 Epoetin alfa Epogen 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0148-10 55513-0148 Epoetin alfa Epogen 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0267-01 55513-0267 Epoetin alfa Epogen 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous April 30, 1990 In Use
55513-0267-10 55513-0267 Epoetin alfa Epogen 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous April 30, 1990 In Use
55513-0283-01 55513-0283 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 5, 1994 In Use
55513-0283-10 55513-0283 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 5, 1994 In Use
55513-0478-01 55513-0478 Epoetin alfa Epogen 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous March 3, 1997 In Use
55513-0478-10 55513-0478 Epoetin alfa Epogen 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous March 3, 1997 In Use
67184-0503-01 67184-0503 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 11, 2018 In Use
00781-3498-94 00781-3498 Arsenic Trioxide Arsenic Trioxide 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous May 19, 2022 In Use

Found 10,000 results in 4 milliseconds — Export these results